116 related articles for article (PubMed ID: 10154087)
1. There's a big niche market for infertility care.
Moore P
Health Care Strateg Manage; 1996 Feb; 14(2):5. PubMed ID: 10154087
[TBL] [Abstract][Full Text] [Related]
2. Egg-sharing in return for subsidized fertility treatment--an ethically justifiable and practical solution to overcome the shortage of donor oocytes for therapeutic cloning.
Heng BC
Med Hypotheses; 2005; 65(5):999-1000. PubMed ID: 16002230
[No Abstract] [Full Text] [Related]
3. Ethical considerations of assisted reproductive technologies. The Ethics Committee of the American Society for Reproductive Medicine.
Fertil Steril; 1997 May; 67(5 Suppl 1):i-iii, 1S-9S. PubMed ID: 9130919
[No Abstract] [Full Text] [Related]
4. [Can one authorize oocyte donation in the Grand Duchy of Luxembourg?].
Arendt J
Bull Soc Sci Med Grand Duche Luxemb; 2012; (1):21-31. PubMed ID: 22822560
[TBL] [Abstract][Full Text] [Related]
5. Ovum donation: examining the new Israeli law.
Gruenbaum BF; Pinchover ZS; Lunenfeld E; Jotkowitz A
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):40-2. PubMed ID: 21824713
[TBL] [Abstract][Full Text] [Related]
6. And baby makes three.
Gemignani J
Bus Health; 1997 Jun; 15(6):55. PubMed ID: 10168150
[No Abstract] [Full Text] [Related]
7. Deliver, then depart.
Begley S; Springen K; Duignan-Cabrera A
Newsweek; 1995 Jul; 126(2):62. PubMed ID: 10143353
[No Abstract] [Full Text] [Related]
8. Healthcare pay: belts tighten--but who feels the squeeze?
Fleshman WJ; Griffin G
J Healthc Resour Manag; 1997; 15(1):7-11. PubMed ID: 10164683
[TBL] [Abstract][Full Text] [Related]
9. Product line management: financial incentives mean healthier patients.
Lohrmann GM; Smith EG
Healthc Financ Manage; 1988 May; 42(5):58-60, 64. PubMed ID: 10287414
[TBL] [Abstract][Full Text] [Related]
10. The ever-rising spiral of technology and cost.
Chetkowski RJ
Fertil Steril; 2006 Jul; 86(1):e7; author reply e8. PubMed ID: 16750204
[No Abstract] [Full Text] [Related]
11. Technology, physician supply reshape obstetrics.
Solovy A
Hospitals; 1989 Mar; 63(6):74. PubMed ID: 2921022
[No Abstract] [Full Text] [Related]
12. The use of donated oocytes for the treatment of infertility.
Talbert LM; Novik BR; Johnson P
N C Med J; 1994 Oct; 55(10):483-6. PubMed ID: 7800062
[No Abstract] [Full Text] [Related]
13. Economic appraisal of in vitro fertilization: discussion paper.
Page H
J R Soc Med; 1989 Feb; 82(2):99-102. PubMed ID: 2494327
[No Abstract] [Full Text] [Related]
14. Worker's comp meets managed care. In the quest for lower costs, a new niche emerges.
Schuckman PV
Infocare; 1998; ():32-4, 36-7. PubMed ID: 10177514
[TBL] [Abstract][Full Text] [Related]
15. Comparison of outcomes and direct cost between minimal stimulation and conventional protocols on ovarian stimulation in in vitro fertilization.
Sophonsritsuk A; Choktanasiri W; Weerakiet S; Rojanasakul A
J Obstet Gynaecol Res; 2005 Oct; 31(5):459-63. PubMed ID: 16176518
[TBL] [Abstract][Full Text] [Related]
16. A bigger brood. As OB/GYN practices grow nationwide, what's good news for the docs can be bad news for hospitals and health plans.
Romano M
Mod Healthc; 2005 Oct; 35(43):28-30. PubMed ID: 16276748
[No Abstract] [Full Text] [Related]
17. [Oocyte donation to be legalized in Sweden. Excellent results reported from other countries].
Söderström-Anttila V; Hovatta O
Lakartidningen; 2002 Jul; 99(30-31):3118-21. PubMed ID: 12198931
[TBL] [Abstract][Full Text] [Related]
18. Opinions of infertile Turkish women on gamete donation and gestational surrogacy.
Baykal B; Korkmaz C; Ceyhan ST; Goktolga U; Baser I
Fertil Steril; 2008 Apr; 89(4):817-22. PubMed ID: 18406837
[TBL] [Abstract][Full Text] [Related]
19. An emerging niche market opportunity. Part I.
Pulaski MJ
Med Group Manage J; 1997; 44(4):69, 72-4, 76 passim. PubMed ID: 10169123
[TBL] [Abstract][Full Text] [Related]
20. [Current practices of oocyte donation in France and Europe].
Letur H
J Gynecol Obstet Biol Reprod (Paris); 2007 Dec; 36(8):727-37. PubMed ID: 17850990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
